Tisagenlecleucel for Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Clinical Outcomes and Long-Term Follow-Up from the JULIET Trial
Highlights
- Tisagenlecleucel induces high overall response rates (52%) with durable complete remissions in relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
- Five-year follow-up from the JULIET trial demonstrates a relapse-free probability of 61% among responders, underscoring sustained efficacy.
- Response and survival correlate with baseline prognostic factors such as International Prognostic Index risk factors, lactate dehydrogenase, and C-reactive protein levels.
- Adverse events including cytokine release syndrome and neurotoxicity are generally manageable, with no new long-term safety signals reported.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.